Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1882)
Drug Name
TAK-875
Synonyms
Fasiglifam; GLP1W4JXAH; TAK 875; TAK-875; TAK875; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; 1000413-72-8; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; CHEMBL1829174; UNII-GLP1W4JXAH; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid
Indication Diabetes mellitus [ICD11: 5A10] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 524.6 Topological Polar Surface Area 108
Heavy Atom Count 37 Rotatable Bond Count 11
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
24857286
PubChem SID
50088191 ; 57154181 ; 134464228 ; 135268194 ; 136349531 ; 136367662 ; 140817135 ; 143499812 ; 152233038 ; 152258229 ; 160647065 ; 160865873 ; 162011413 ; 162202766 ; 164044689 ; 170501170 ; 172232430 ; 172919610 ; 174006778 ; 174525708 ; 174526154 ; 178103098 ; 185967135 ; 191112353 ; 196409677 ; 198984389 ; 203355926 ; 223375341 ; 224346112 ; 226560798 ; 242587051 ; 245772988 ; 249735423 ; 252110185 ; 252151428 ; 252216368 ; 252450486 ; 252810271
CAS Number
1000413-72-8
TTD Drug ID
D0V1WQ
Formula
C29H32O7S
Canonical SMILES
CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)C(CO4)CC(=O)O)C)OCCCS(=O)(=O)C
InChI
1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
InChIKey
BZCALJIHZVNMGJ-HSZRJFAPSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Fasiglifam-G DM006014 N. A. Conjugation - Conjugation 1 [2]
Fasiglifam-Tau DM006013 N. A. Unclear 1 [2]
T-167642 DM006015
129162798
Unclear 1 [2]
TAK-875 Metabolite M-I DM006011 N. A. Unclear 1 [2]
TAK-875 Metabolite M-I-G DM006012
137331906
Conjugation - Conjugation 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006472 TAK-875 TAK-875 Metabolite M-I Unclear CYP3A4 ... [2]
MR006474 TAK-875 Fasiglifam-Tau Unclear Unclear [2]
MR006475 TAK-875 Fasiglifam-G Conjugation - Conjugation CYP3A4 ... [2]
MR006476 TAK-875 T-167642 Unclear UGT1A3 [2]
MR006473 TAK-875 Metabolite M-I TAK-875 Metabolite M-I-G Conjugation - Conjugation UGT1A3 [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DME0041 Homo sapiens
UD13_HUMAN
2.4.1.17
[2]
References
1 ClinicalTrials.gov (NCT01609582) Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease.
2 Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.